{"id":"W4385702448","doi":"10.1097/01.hs9.0000971168.59900.67","title":"P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); Cohort; Salvage therapy; Chemotherapy; Gastroenterology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002859078,0.0008809789,0.001984766,0.0004965762,0.0003306917,0.001211216,0.0008447289,0.001192299,0.006170831],"category_scores_gemma":[0.00220507,0.0003545796,0.002085102,0.0007951447,0.0002970664,0.0008623304,0.0003910808,0.001838967,0.001770028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008143624,"about_ca_system_score_gemma":0.001215719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001320667,"about_ca_topic_score_gemma":0.003469137,"domain_scores_codex":[0.999072,0.0003829066,0.000114013,0.0001114486,0.0002178406,0.0001018013],"domain_scores_gemma":[0.9979175,0.0004972756,0.0007144081,0.0001327012,0.000359618,0.000378626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3725352,0.01248971,0.04510557,0.005947199,0.01063827,0.001083486,0.0003412327,0.003405265,0.04858573,0.0002732495,0.07883591,0.4207593],"study_design_scores_gemma":[0.3454732,0.2054275,0.2944585,0.0008829613,0.01664306,0.003545599,0.0002067542,0.002157504,0.01145421,0.0006901487,0.118859,0.0002015162],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8249877,0.04820788,0.003235489,0.005818848,0.00148172,0.006150652,0.08700667,0.000711936,0.02239916],"genre_scores_gemma":[0.8315693,0.02027549,0.008292733,0.008855051,0.001577489,0.005749379,0.112044,0.0002819028,0.01135472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006170831,"threshold_uncertainty_score":0.02064353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03137807776785468,"score_gpt":0.3217374355978094,"score_spread":0.2903593578299547,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}